Mymetics Corp
OTC:MYMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mymetics Corp
PP&E Net
Mymetics Corp
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mymetics Corp
OTC:MYMX
|
PP&E Net
€159k
|
CAGR 3-Years
-17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
PP&E Net
$247.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
22%
|
CAGR 10-Years
69%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
PP&E Net
CHf18.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
28%
|
CAGR 10-Years
5%
|
|
|
Idorsia Ltd
SIX:IDIA
|
PP&E Net
CHf190.9m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
PP&E Net
CHf4.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
PP&E Net
CHf2.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Mymetics Corp
Glance View
Mymetics Corp. is a biotechnology company, which engages in the research and development of virosome based vaccines. The company is headquartered in Epalinges, Vaud and currently employs 8 full-time employees. The firm is focused on developing vaccines for infectious diseases. The firm has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
See Also
What is Mymetics Corp's PP&E Net?
PP&E Net
159k
EUR
Based on the financial report for Dec 31, 2022, Mymetics Corp's PP&E Net amounts to 159k EUR.
What is Mymetics Corp's PP&E Net growth rate?
PP&E Net CAGR 5Y
20%
Over the last year, the PP&E Net growth was -43%. The average annual PP&E Net growth rates for Mymetics Corp have been -17% over the past three years , 20% over the past five years .
